A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Selumetinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms SELECT-3
- Sponsors AstraZeneca
- 18 Oct 2017 Results (n=21) presented at the 18th World Conference on Lung Cancer.
- 26 Sep 2017 Results published in the British Journal of Cancer.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress